Drug Profile

ARQ 234

Alternative Names: ARQ-234; DS-234

Latest Information Update: 27 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ducentis BioTherapeutics
Class Anti-inflammatories; Recombinant fusion proteins; Skin disorder therapies
Mechanism of Action CD200R1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Aug 2024 Arcutis Biotherapeutics plans to file an IND application for Atopic dermatitis in 2025
17 Mar 2023 Arcutis Biotherapeutics has patents pending for ARQ 234 and other CD200 mutant proteins in Brazil, Canada, Europe, Hong Kong, India, Korea, New Zealand, Singapore
31 Dec 2022 Arcutis Biotherapeutics has patent protection for ARQ 234 and other CD200 mutant protein in USA, Australia, China, Eurasia, Israel, Japan, Mexico, South Korea and South Africa

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com